Teva Pharmaceutical Industries Ltd. $TEVA Holdings Boosted by Harel Insurance Investments & Financial Services Ltd.

Harel Insurance Investments & Financial Services Ltd. boosted its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 51.4% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 33,390,327 shares of the company’s stock after purchasing an additional 11,334,780 shares during the period. Teva Pharmaceutical Industries comprises approximately 6.4% of Harel Insurance Investments & Financial Services Ltd.’s investment portfolio, making the stock its 2nd largest position. Harel Insurance Investments & Financial Services Ltd.’s holdings in Teva Pharmaceutical Industries were worth $559,622,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in TEVA. Strs Ohio lifted its holdings in shares of Teva Pharmaceutical Industries by 415.3% in the 2nd quarter. Strs Ohio now owns 789,145 shares of the company’s stock worth $13,226,000 after acquiring an additional 636,015 shares during the last quarter. Assetmark Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 137.2% during the 2nd quarter. Assetmark Inc. now owns 20,075 shares of the company’s stock valued at $336,000 after purchasing an additional 11,613 shares during the last quarter. Hantz Financial Services Inc. raised its position in Teva Pharmaceutical Industries by 1,351.1% in the 2nd quarter. Hantz Financial Services Inc. now owns 6,138 shares of the company’s stock worth $103,000 after purchasing an additional 5,715 shares during the period. Migdal Insurance & Financial Holdings Ltd. lifted its stake in Teva Pharmaceutical Industries by 8.9% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,685,422 shares of the company’s stock worth $480,768,000 after purchasing an additional 2,350,000 shares during the last quarter. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its position in Teva Pharmaceutical Industries by 18.6% during the second quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 346,104 shares of the company’s stock valued at $5,801,000 after buying an additional 54,300 shares during the period. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Price Performance

TEVA opened at $20.50 on Friday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06. The stock has a market capitalization of $23.51 billion, a PE ratio of -128.09, a price-to-earnings-growth ratio of 1.11 and a beta of 0.71. The stock’s 50 day moving average price is $19.28 and its 200-day moving average price is $17.54. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. The company had revenue of $4.18 billion during the quarter, compared to analyst estimates of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The firm’s revenue was up .3% on a year-over-year basis. During the same quarter last year, the firm posted $0.61 earnings per share. On average, equities research analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on TEVA shares. JPMorgan Chase & Co. lifted their price objective on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock an “overweight” rating in a report on Friday, October 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. UBS Group lifted their price target on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Finally, Wall Street Zen raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 11th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of “Buy” and an average price target of $25.57.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.